3P Biopharmaceuticals, a contract development and manufacturing organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, a UK based biotech, to collaborate in the development of a novel anti-tumor treatment.

3P Biopharmaceuticals and In3Bio began their partnership in early 2019 with 3P Biopharmaceuticals being selected to be responsible for technology transfer, process development, analytical methods development, scale-up and cGMP production for clinical studies.

In3Bio’s candidate molecule is IN02, a bi-specific biological molecule that was identified through designing fusions of molecules with high binding potential for targeting growth factors. The technology employed by In3Bio produces new molecules specific to one or multiple growth factors at the same time. In this way, these new candidates have demonstrated a wide potential in the treatment of different cancer indications using established preclinical models, opening the door for developing an effective anti-tumor therapy.
 
“It is an honor to help develop an anticancer treatment and do our best in the field of oncology with the hope of ultimately contributing to a positive effect on society,” said Dámaso Molero, chief executive officer, 3P Bio. “This innovative project strengthens the experience of 3P Biopharmaceuticals to develop complex therapeutic products applied to health and
places us among the most competitive CDMOs in Europe.”

Erik D’Hondt, chief executive officer, In3Bio, said, “We at IN3BIO are pleased to cooperate with 3P Biopharmaceuticals, a CDMO with solid and broad experience to support IN3BIO for preparing clinical batch of a chimeric biological molecule to be used in the clinic.”